Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Flu illness count nears 5 million, with New York City among the hardest hit - 2Flu season is just beginning, but doctors are already on high alert
- 3Russia Establishing Long-Range Drone Bases In Belarus, Warns Ukraine
- 4Journey Travel Objections for Your Next Experience
- 5EU waters down plans to end new petrol and diesel car sales by 2035
- Sexual violence part of 'everyday life' in parts of Sudan, charity says
- International issues on the agenda as Frances's Macron visits China
- Somalia set for 'historic' first offshore oil drilling
- Explosions at Burundi ammunition depot kill civilians, witnesses say
- 2 bright planets light up April evenings — here's where and when to look
- Vote In favor of Your Number one Sort Of Blossoms
- Timex Gives Its Classic Affordable Field Watch a Tactical, Milspec Makeover
- Figure out How to Explore Land Close to 5G Pinnacles
- Haifa refinery said hit in latest Iranian missile barrage
